MX2017011635A - Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida. - Google Patents
Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida.Info
- Publication number
- MX2017011635A MX2017011635A MX2017011635A MX2017011635A MX2017011635A MX 2017011635 A MX2017011635 A MX 2017011635A MX 2017011635 A MX2017011635 A MX 2017011635A MX 2017011635 A MX2017011635 A MX 2017011635A MX 2017011635 A MX2017011635 A MX 2017011635A
- Authority
- MX
- Mexico
- Prior art keywords
- combinations
- fbxw7
- stereoisomer
- solvate
- hydrate
- Prior art date
Links
- NTTQCLSBWRKUIJ-UHFFFAOYSA-N 2,3-dihydroimidazo[1,2-c]quinazoline Chemical class C1=CC=C2C3=NCCN3C=NC2=C1 NTTQCLSBWRKUIJ-UHFFFAOYSA-N 0.000 title abstract 2
- 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 abstract 2
- 101710105178 F-box/WD repeat-containing protein 7 Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 abstract 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000035945 sensitivity Effects 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- KVBXVOSVQPIXSL-UHFFFAOYSA-N 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine Chemical class C1=CC=C2SC(C=3C=CN4N=CN=C(C=34)N)=CC2=C1 KVBXVOSVQPIXSL-UHFFFAOYSA-N 0.000 abstract 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 abstract 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 abstract 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 abstract 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 abstract 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 abstract 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 abstract 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 abstract 1
- 101001120097 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit beta Proteins 0.000 abstract 1
- 101001098116 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit gamma Proteins 0.000 abstract 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 abstract 1
- 101000595741 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 abstract 1
- 101000595746 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 abstract 1
- 101000595751 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 abstract 1
- 101000692672 Homo sapiens Phosphoinositide 3-kinase regulatory subunit 4 Proteins 0.000 abstract 1
- 101000692678 Homo sapiens Phosphoinositide 3-kinase regulatory subunit 5 Proteins 0.000 abstract 1
- -1 PI K3R1 Proteins 0.000 abstract 1
- 102100026177 Phosphatidylinositol 3-kinase regulatory subunit beta Human genes 0.000 abstract 1
- 102100037553 Phosphatidylinositol 3-kinase regulatory subunit gamma Human genes 0.000 abstract 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 abstract 1
- 102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 abstract 1
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 abstract 1
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 abstract 1
- 102100026481 Phosphoinositide 3-kinase regulatory subunit 4 Human genes 0.000 abstract 1
- 102100026478 Phosphoinositide 3-kinase regulatory subunit 5 Human genes 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009434 installation Methods 0.000 abstract 1
- 238000007912 intraperitoneal administration Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a: * combinaciones de: componente A: uno o más compuestos de 2,3-dihidroimidazo[1,2-c]qui nazolina de fórmula general (A1) o (A2), o una sal, solvato, hidrato o estereoisómero fisiológicamente aceptable de los mismos; componente B: uno o más compuestos de 5-(1-benzotiofen-2-il)pirrolo[2,l-f][1,2,4]-triazin-4-amina sustituida de fórmula general (B), o una sal, solvato, hidrato o estereoisómero fisiológicamente aceptable de los mismos; en las cuales opcionalmente algunos o todos los componentes están en forma de una formulación farmacéutica la cual está lista para su utilización y se administra simultánea, concurrente, separada o consecutivamente. dependientemente uno del otro por la vía oral, intravenosa, tópica, instilaciones locales, intraperitoneal o nasal; * uso de dichas combinaciones para la preparación de un medicamento para el tratamiento o profilaxis de un cáncer; * un kit que comprende ese tipo de combinación; * uso de biomarcadores que es la pérdida del supresor tumoral PTEN o FBXW7, para predecir la sensibilidad y/o la resistencia de un paciente con cáncer a dicho compuesto y proporcionar una dosis fundamentada para aumentar la sensibilidad y/o para solucionar la resistencia; * un método para determinar la pérdida del supresor tumoral PTEN o FBXW7; y * un método para determinar perturbaciones en PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R4, PIK3R5, FGFR1, FGFR2, FGFR3 y/o FGFR4. Pérdida de PTEN y alteración de PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, P1K3R4, PIK3R5, FGFR1, FGFR2, FGFR3 y/o FGFR4. (ver Graficas).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562130418P | 2015-03-09 | 2015-03-09 | |
| PCT/EP2016/054727 WO2016142312A1 (en) | 2015-03-09 | 2016-03-07 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017011635A true MX2017011635A (es) | 2018-02-09 |
Family
ID=55538186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017011635A MX2017011635A (es) | 2015-03-09 | 2016-03-07 | Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10406162B2 (es) |
| EP (1) | EP3268490B1 (es) |
| JP (1) | JP6867295B2 (es) |
| KR (1) | KR20180013851A (es) |
| CN (1) | CN107864625B (es) |
| AU (1) | AU2016231259A1 (es) |
| BR (1) | BR112017019188A2 (es) |
| CA (1) | CA2978830A1 (es) |
| EA (1) | EA201791974A1 (es) |
| IL (1) | IL254167A0 (es) |
| MX (1) | MX2017011635A (es) |
| PH (1) | PH12017501643A1 (es) |
| SG (1) | SG11201707240SA (es) |
| SV (1) | SV2017005530A (es) |
| WO (1) | WO2016142312A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| US9999623B2 (en) | 2013-04-08 | 2018-06-19 | Bayer Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| AU2016378723B2 (en) | 2015-12-22 | 2021-09-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| EP3426657B1 (en) | 2016-03-08 | 2022-07-13 | Bayer Pharma Aktiengesellschaft | 2 amino n [7 methoxy 2, 3-dihydroimidazo-[1, 2-c]quinazolin-5-yl]pyrimidine 5 carboxamides |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| US10925880B2 (en) | 2016-09-23 | 2021-02-23 | Bayer Pharma Aktiengesellschaft | Combination of PI3K-inhibitors |
| MA49458A (fr) | 2017-06-21 | 2020-04-29 | SHY Therapeutics LLC | Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques |
| WO2019002068A1 (en) | 2017-06-28 | 2019-01-03 | Bayer Consumer Care Ag | COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST |
| JP7341122B2 (ja) * | 2017-08-15 | 2023-09-08 | 石薬集団中奇制薬技術（石家庄）有限公司 | Ｆｇｆｒ阻害剤及びその医薬品の用途 |
| WO2019105734A1 (en) * | 2017-11-28 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib |
| EP3898609A1 (en) | 2018-12-19 | 2021-10-27 | Shy Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| CN111500587A (zh) * | 2020-04-15 | 2020-08-07 | 湖南省科域生物医药科技有限公司 | Pgr作为治疗子宫内膜异位症的产品中的用途及其检测pgr的试剂盒 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2042504E (pt) | 2002-09-30 | 2011-09-07 | Bayer Schering Pharma Ag | Derivados da azolepirimidina fundida |
| AR064106A1 (es) | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| JP5620275B2 (ja) | 2008-01-14 | 2014-11-05 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 超増殖性疾患及び脈管形成に関連する疾病を処理するために有用なスルホン置換された２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン誘導体類 |
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| BR112012026480A2 (pt) * | 2010-04-16 | 2016-08-16 | Bayer Ip Gmbh | combinações contendo 2,3-di-hidroimidazo[1,2-c]quinazolina substituída |
| JO3733B1 (ar) | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
| EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| CA2850836A1 (en) * | 2011-10-15 | 2013-04-18 | Genentech, Inc. | Methods of using scd1 antagonists |
| UY34484A (es) * | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| US9999623B2 (en) | 2013-04-08 | 2018-06-19 | Bayer Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas |
| WO2014191938A1 (en) | 2013-05-31 | 2014-12-04 | Novartis Ag | Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer |
| CN105934256B (zh) | 2013-12-03 | 2019-12-27 | 拜耳制药股份公司 | Pi3k-抑制剂的组合产品 |
| EP3018131A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| CA2978807A1 (en) | 2015-03-09 | 2016-09-15 | Bayer Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
| MA43957A (fr) | 2016-02-01 | 2018-12-12 | Bayer Pharma AG | Biomarqueurs de copanlisib |
| US20190382839A1 (en) | 2016-02-01 | 2019-12-19 | Bayer Pharma Aktiengesellschaft | Copanlisib biomarkers |
| EP3426657B1 (en) | 2016-03-08 | 2022-07-13 | Bayer Pharma Aktiengesellschaft | 2 amino n [7 methoxy 2, 3-dihydroimidazo-[1, 2-c]quinazolin-5-yl]pyrimidine 5 carboxamides |
| PH12021551812A1 (en) * | 2019-01-31 | 2022-03-21 | Bayer Ag | The monohydrate of rogaratinib hydrochloride and solid states thereof |
-
2016
- 2016-03-07 EA EA201791974A patent/EA201791974A1/ru unknown
- 2016-03-07 AU AU2016231259A patent/AU2016231259A1/en not_active Abandoned
- 2016-03-07 SG SG11201707240SA patent/SG11201707240SA/en unknown
- 2016-03-07 MX MX2017011635A patent/MX2017011635A/es unknown
- 2016-03-07 CN CN201680026204.XA patent/CN107864625B/zh not_active Expired - Fee Related
- 2016-03-07 KR KR1020177027608A patent/KR20180013851A/ko not_active Withdrawn
- 2016-03-07 CA CA2978830A patent/CA2978830A1/en not_active Abandoned
- 2016-03-07 EP EP16710115.3A patent/EP3268490B1/en active Active
- 2016-03-07 US US15/556,908 patent/US10406162B2/en not_active Expired - Fee Related
- 2016-03-07 WO PCT/EP2016/054727 patent/WO2016142312A1/en not_active Ceased
- 2016-03-07 JP JP2017548224A patent/JP6867295B2/ja not_active Expired - Fee Related
- 2016-03-07 BR BR112017019188-1A patent/BR112017019188A2/pt not_active Application Discontinuation
-
2017
- 2017-08-27 IL IL254167A patent/IL254167A0/en unknown
- 2017-09-08 SV SV2017005530A patent/SV2017005530A/es unknown
- 2017-09-08 PH PH12017501643A patent/PH12017501643A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016142312A1 (en) | 2016-09-15 |
| US10406162B2 (en) | 2019-09-10 |
| CN107864625A (zh) | 2018-03-30 |
| BR112017019188A2 (pt) | 2018-04-24 |
| KR20180013851A (ko) | 2018-02-07 |
| SV2017005530A (es) | 2018-10-02 |
| PH12017501643A1 (en) | 2018-03-12 |
| IL254167A0 (en) | 2017-10-31 |
| CN107864625B (zh) | 2021-05-28 |
| US20180055851A1 (en) | 2018-03-01 |
| JP6867295B2 (ja) | 2021-04-28 |
| SG11201707240SA (en) | 2017-10-30 |
| CA2978830A1 (en) | 2016-09-15 |
| EP3268490A1 (en) | 2018-01-17 |
| EP3268490B1 (en) | 2020-07-08 |
| EA201791974A1 (ru) | 2018-05-31 |
| AU2016231259A1 (en) | 2017-09-21 |
| JP2018510869A (ja) | 2018-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017011635A (es) | Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida. | |
| TN2017000385A1 (en) | Use of substituted 2,3-dihydroimidaz0[1,2-c]quinazolines. | |
| JP2016501221A5 (es) | ||
| EA201000090A1 (ru) | Тризамещенные производные пиримидина для лечения пролиферативных заболеваний | |
| EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
| TN2012000493A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations | |
| PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
| TN2013000237A1 (en) | Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor | |
| TN2013000293A1 (en) | Derivatives of azaindazole or diazaindazole type as medicament | |
| NZ708563A (en) | Treatment of cancers using pi3 kinase isoform modulators | |
| HRP20220619T1 (hr) | Postupci za liječenje ar+ raka dojke | |
| TR201819653T4 (tr) | Karaciğer kanserinin tedavisinde kullanılmaya yönelik organik bileşik. | |
| AU2011310532A8 (en) | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations | |
| EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
| WO2009007748A3 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| WO2009007749A3 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| BR112015022846A2 (pt) | uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo | |
| MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. | |
| TW201613577A (en) | Pharmaceutical combinations | |
| MX2015011588A (es) | Tratamiento de combinacion. | |
| BR112018003335A2 (pt) | composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona | |
| MY169449A (en) | Therapeutic treatment | |
| RU2015111171A (ru) | Фармацевтическая комбинация, включающая ингибитор фосфатидилинозитол 3-киназы и ингибитор ароматазы |